BNP Paribas Financial Markets’s Matinas BioPharma MTNB Stock Holding History

BNP Paribas Financial Markets’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2	Closed	-$37	–	3988
2023 Q1	$37	Hold	2	–	–	﹤0.01%	3803
2022 Q4	$40	Buy	+2	New	+$67	﹤0.01%	3980
2021 Q1	–	Sell	-1	Closed	-$34	–	4095
2020 Q4	$34	Hold	1	–	–	﹤0.01%	4091
2020 Q3	$19	Hold	1	–	–	﹤0.01%	4159
2020 Q2	$19	Hold	1	–	–	﹤0.01%	4251
2020 Q1	$15	Hold	1	–	–	﹤0.01%	4275
2019 Q4	$57	Hold	1	–	–	﹤0.01%	4355
2019 Q3	$17	Hold	1	–	–	﹤0.01%	4475
2019 Q2	$23	Hold	1	–	–	﹤0.01%	4502
2019 Q1	$27	Sell	1 -95	-99%	-$5.12K	﹤0.01%	4245
2018 Q4	$2.85K	Hold	96	–	–	﹤0.01%	3733
2018 Q3	$4.41K	Hold	96	–	–	﹤0.01%	4110
2018 Q2	$2.08K	Sell	96 -307	-76%	-$8.87K	﹤0.01%	4249
2018 Q1	$15.4K	Buy	403 +71	+21%	+$3.75K	﹤0.01%	3962
2017 Q4	$19.3K	Buy	332 +229	+222%	+$14.7K	﹤0.01%	3967
2017 Q3	$6.8K	Sell	103 -8	-7%	-$534	﹤0.01%	3946
2017 Q2	$9.35K	Buy	+111	New	+$14.9K	﹤0.01%	3955

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

BNP Paribas Financial Markets's MTNB Position: Q2 2023 in Review

BNP Paribas Financial Markets sold out of Matinas BioPharma (MTNB) in Q2 2023, closing a stake of 2 shares — an estimated $37 sold.

BNP Paribas Financial Markets first reported a position in MTNB in Q2 2017 and held it in 17 quarters. The position peaked at $19.3K in Q4 2017. 51 funds tracked by Wall St. Rank hold MTNB as of Q2 2023.

BNP Paribas Financial Markets reported no remaining Matinas BioPharma position as of Q2 2023 after selling out during the quarter.
BNP Paribas Financial Markets sold 2 Matinas BioPharma shares in Q2 2023, an estimated $37.
BNP Paribas Financial Markets first reported a position in Matinas BioPharma in Q2 2017 and held it in 17 quarters.
BNP Paribas Financial Markets's Matinas BioPharma position peaked at $19.3K in Q4 2017.
51 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2023.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2023, filed 9 Aug 2023.